These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22826520)

  • 1. Recirculatory pharmacokinetic modeling: what goes around, comes around.
    Krejcie TC; Avram MJ
    Anesth Analg; 2012 Aug; 115(2):223-6. PubMed ID: 22826520
    [No Abstract]   [Full Text] [Related]  

  • 2. Context sensitive decrement times of remimazolam.
    Schnider T; Minto C
    Anesth Analg; 2013 Jul; 117(1):285. PubMed ID: 23788743
    [No Abstract]   [Full Text] [Related]  

  • 3. Remimazolam: new beginnings or just a me-too?
    Sneyd JR
    Anesth Analg; 2012 Aug; 115(2):217-9. PubMed ID: 22826518
    [No Abstract]   [Full Text] [Related]  

  • 4. New horizons in sedative hypnotic drug development: fast, clean, and soft.
    Johnson KB
    Anesth Analg; 2012 Aug; 115(2):220-2. PubMed ID: 22826519
    [No Abstract]   [Full Text] [Related]  

  • 5. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
    Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics.
    Antonik LJ; Goldwater DR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):274-83. PubMed ID: 22190555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic modeling and ICU sedation: unexplored territories.
    Bailey JM
    Anesthesiology; 2001 Aug; 95(2):281-2. PubMed ID: 11506095
    [No Abstract]   [Full Text] [Related]  

  • 8. Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics.
    Vuyk J; Lichtenbelt BJ; Olofsen E; van Kleef JW; Dahan A
    Anesth Analg; 2009 May; 108(5):1522-30. PubMed ID: 19372331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of time-dependent inactivation on the estimation of enzyme kinetic parameters for midazolam.
    Giragossian C; LaPerle J; Kosa RE; Gillian S
    Drug Metab Lett; 2009 Jan; 3(1):45-53. PubMed ID: 19356116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semi-mechanistic autoinduction model of midazolam in critically ill patients: population pharmacokinetic analysis.
    Aoyama T; Hirata K; Yamamoto Y; Yokota H; Hayashi H; Aoyama Y; Matsumoto Y
    J Clin Pharm Ther; 2016 Aug; 41(4):392-8. PubMed ID: 27178380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A maturation model for midazolam clearance.
    Anderson BJ; Larsson P
    Paediatr Anaesth; 2011 Mar; 21(3):302-8. PubMed ID: 20704661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of an alternative generic model for predicting pharmacokinetic changes during physiological stress.
    Peng HT; Edginton AN; Cheung B
    J Clin Pharmacol; 2013 Oct; 53(10):1048-57. PubMed ID: 23852614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzodiazepine hypnotics: sorting the pharmacokinetic facts.
    Greenblatt DJ
    J Clin Psychiatry; 1991 Sep; 52 Suppl():4-10. PubMed ID: 1680125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam.
    Fiset P; Lemmens HL; Egan TD; Shafer SL; Stanski DR
    Clin Pharmacol Ther; 1995 Nov; 58(5):567-82. PubMed ID: 7586951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Propofol reduces the distribution and clearance of midazolam.
    Lichtenbelt BJ; Olofsen E; Dahan A; van Kleef JW; Struys MM; Vuyk J
    Anesth Analg; 2010 Jun; 110(6):1597-606. PubMed ID: 20435936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients.
    Boulieu R; Lehmann B; Salord F; Fisher C; Morlet D
    Eur J Drug Metab Pharmacokinet; 1998; 23(2):255-8. PubMed ID: 9725490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the estimation of midazolam concentrations and pharmacokinetic parameters in intensive care patients using a bayesian pharmacokinetic software (PKS) according to sparse sampling approach.
    Bolon M; Bastien O; Flamens C; Paulus S; Salord F; Boulieu R
    J Pharm Pharmacol; 2003 Jun; 55(6):765-71. PubMed ID: 12841936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of medetomidine, atipamezole and midazolam in pig plasma by liquid chromatography-mass spectrometry.
    Kanazawa H; Nishimura R; Sasaki N; Takeuchi A; Takai N; Nagata Y; Matsushima Y
    Biomed Chromatogr; 1995; 9(4):188-91. PubMed ID: 8520209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal midazolam in piglets: pharmacodynamics (0.2 vs 0.4 mg/kg) and pharmacokinetics (0.4 mg/kg) with bioavailability determination.
    Lacoste L; Bouquet S; Ingrand P; Caritez JC; Carretier M; Debaene B
    Lab Anim; 2000 Jan; 34(1):29-35. PubMed ID: 10759364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.